Astrum Therapeutics to begin clinical trials on Type 2 diabetes compounds
Friday, 29 July, 2005
Brisbane biotech BioProspect (ASX:BPO) has hit heavy cloud in its attempts to secure international partners to commercialise its novel plant-derived pesticides, but feels the sun is beginning to shine on its investment in Astrum Therapeutics.
BioProspect bought a one-third stake in Astrum on April 1, and the Melbourne drug-developer has announced it is moving to synthesise sufficient quantities of its two candidate compounds for treating Type 2 (non-insulin dependent) diabetes for clinical trials.
Astrum will begin recruiting volunteers for the trials by the end of the year -- it has not revealed the molecular targets for the molecules, but said they prevent the death of insulin-secreting pancreatic islet cells.
The company has also completed patent applications for combination therapies of its compounds, targeting the three major metabolic problems associated with type 2 diabetes -- cardiovascular disease, inflammation and neurological complications.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
